Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
The growing clinical success of hematopoietic stem/progenitor cell (HSPC) gene therapy (GT) relies on the development of viral vectors as portable "Trojan horses" for safe and efficient gene transfer. The recent advent of novel technologies enabling site-specific gene editing is broadening the scope and means of GT, paving the way to more precise genetic engineering and expanding the spectrum of diseases amenable to HSPC-GT. Here, we provide an overview of state-of-the-art and prospective developments of the HSPC-GT field, highlighting how advances in biological characterization and manipulation of HSPCs will enable the design of the next generation of these transforming therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Highly accurate protein structure prediction for the human proteome
Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03828-1 · Cited by 3,025
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
Self-citationGenome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0561-9 · Cited by 2,237
A guide to machine learning for biologists
Greener, J. G., Kandathil, S. M., Moffat, L., & Jones, D. T. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00407-0 · Cited by 2,127
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Research works printed but not linked: 204
- Ferrari, 2021, Gene therapy using haematopoietic stem and progenitor cells, Nat. Rev. Genet., 22, 216, 10.1038/s41576-020-00298-5 · DOI · Paper page
- Aiuti, 2002, Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning, Science, 10.1126/science.1070104 · DOI · Paper page
- Cavazzana-Calvo, 2000, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, Science, 288, 669, 10.1126/science.288.5466.669 · DOI · Paper page
- Hacein-Bey-Abina, 2002, Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy, N. Engl. J. Med., 346, 1185, 10.1056/NEJMoa012616 · DOI · Paper page
- Gaspar, 2004, Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector, Lancet, 364, 2181, 10.1016/S0140-6736(04)17590-9 · DOI · Paper page
- Hacein-Bey-Abina, 2003, LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 · DOI · Paper page
- Naldini, 2016, Lentiviral vectors, two decades later, Science, 353, 1101, 10.1126/science.aah6192 · DOI · Paper page
- Kohn, 2021, Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency, N. Engl. J. Med., 384, 2002, 10.1056/NEJMoa2027675 · DOI · Paper page
- Cicalese, 2018, Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety, Mol. Ther., 26, 917, 10.1016/j.ymthe.2017.12.022 · DOI
- de Ravin, 2016, Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency, Sci. Transl. Med., 8, 10.1126/scitranslmed.aad8856 · DOI · Paper page
- Magnani, 2022, Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome, Nat. Med., 28, 71, 10.1038/s41591-021-01641-x · DOI · Paper page
- Ferrua, 2019, Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study, Lancet. Haematol., 6, 10.1016/S2352-3026(19)30021-3 · DOI · Paper page
- Kohn, 2020, Lentiviral gene therapy for X-linked chronic granulomatous disease., Nat Med, 26, 200, 10.1038/s41591-019-0735-5 · DOI · Paper page
- Gentner, 2021, Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome, N. Engl. J. Med., 385, 1929, 10.1056/NEJMoa2106596 · DOI · Paper page
- Marktel, 2019, Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia, Nat. Med., 25, 234, 10.1038/s41591-018-0301-6 · DOI · Paper page
- Locatelli, 2022, Betibeglogene Autotemcel Gene Therapy for Non–β 0/β 0 Genotype β-Thalassemia, N. Engl. J. Med., 386, 415, 10.1056/NEJMoa2113206 · DOI · Paper page
- Río, 2019, Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia, Nat. Med., 25, 1396, 10.1038/s41591-019-0550-z · DOI · Paper page
- Tucci, 2022, A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders, Nat. Commun., 13, 10.1038/s41467-022-28762-2 · DOI · Paper page
- Czechowicz, 2019, Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation, Nat. Commun., 10, 10.1038/s41467-018-08201-x · DOI · Paper page
- Kwon, 2019, Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice, Blood, 133, 2104, 10.1182/blood-2018-06-853879 · DOI · Paper page
- Palchaudhuri, 2016, Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin, Nat. Biotechnol., 34, 738, 10.1038/nbt.3584 · DOI · Paper page
- Biffi, 2013, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy, Science, 341, 10.1126/science.1233158 · DOI · Paper page
- Peviani, 2023, An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model., EMBO Mol. Med., 10.15252/emmm.202215968 · DOI
- Birocchi, 2022, Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models, Sci. Transl. Med., 14, 4106, 10.1126/scitranslmed.abl4106 · DOI
- Mucci, 2021, Myeloid cell-based delivery of IFN-γ reprograms the leukemia microenvironment and induces anti-tumoral immune responses, EMBO Mol. Med., 13, 10.15252/emmm.202013598 · DOI
- Escobar, 2018, Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens, Nat. Commun., 9, 10.1038/s41467-018-05315-0 · DOI
- Craigie, 2014, Host Factors in Retroviral Integration and the Selection of Integration Target Sites, Microbiol. Spectr., 2, 10.1128/microbiolspec.MDNA3-0026-2014 · DOI · Paper page
- Hacein-Bey Abina, 2015, Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome, JAMA, 313, 1550, 10.1001/jama.2015.3253 · DOI · Paper page
- Cesana, 2021, Retrieval of vector integration sites from cell-free DNA, Nat. Med., 27, 1458, 10.1038/s41591-021-01389-4 · DOI · Paper page
- Six, 2020, Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs, Blood, 135, 1219, 10.1182/blood.2019002350 · DOI · Paper page
- Scala, 2018, Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans, Nat. Med., 24, 1683, 10.1038/s41591-018-0195-3 · DOI · Paper page
- Scala, 2019, In vivo dynamics of human hematopoietic stem cells: novel concepts and future directions, Blood Adv., 3, 1916, 10.1182/bloodadvances.2019000039 · DOI · Paper page
- Kebriaei, 2017, Gene Therapy with the Sleeping Beauty Transposon System, Trends Genet., 33, 852, 10.1016/j.tig.2017.08.008 · DOI
- Tipanee, 2017, Preclinical and clinical advances in transposon-based gene therapy, Biosci. Rep., 37, 10.1042/BSR20160614 · DOI · Paper page
- Moretti, 2022, The Past, Present, and Future of Non-Viral CAR T Cells, Front. Immunol., 13, 867013, 10.3389/fimmu.2022.867013 · DOI
- Scully, 2019, DNA double-strand break repair-pathway choice in somatic mammalian cells, Nat. Rev. Mol. Cell Biol., 20, 698, 10.1038/s41580-019-0152-0 · DOI · Paper page
- Shy, 2022, High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails, Nat. Biotechnol., 2022, 1
- Pattabhi, 2019, Vivo Outcome of Homology-Directed Repair at the HBB Gene in HSC Using Alternative Donor Template Delivery Methods, Mol. Ther. Nucleic Acids, 17, 277, 10.1016/j.omtn.2019.05.025 · DOI · Paper page
- Romero, 2019, Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates, Mol. Ther., 27, 1389, 10.1016/j.ymthe.2019.05.014 · DOI · Paper page
- Ferrari, 2020, Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking, Nat. Biotechnol., 38, 1298, 10.1038/s41587-020-0551-y · DOI · Paper page
- Demirci, 2020, BCL11A enhancer–edited hematopoietic stem cells persist in rhesus monkeys without toxicity, J. Clin. Invest., 130, 6677, 10.1172/JCI140189 · DOI · Paper page
- Charlesworth, 2018, Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting, Mol. Ther. Nucleic Acids, 12, 89, 10.1016/j.omtn.2018.04.017 · DOI
- Lattanzi, 2021, Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease, Sci. Transl. Med., 13, 10.1126/scitranslmed.abf2444 · DOI · Paper page
- Lomova, 2019, Improving Gene Editing Outcomes in Human Hematopoietic Stem and Progenitor Cells by Temporal Control of DNA Repair, Stem Cell., 37, 284, 10.1002/stem.2935 · DOI · Paper page
- Shin, 2020, Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor Cells, Cell Rep., 32, 10.1016/j.celrep.2020.108093 · DOI
- Canny, 2018, Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR–Cas9 genome-editing efficiency, Nat. Biotechnol., 36, 95, 10.1038/nbt.4021 · DOI · Paper page
- Rai, 2020, Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome, Nat. Commun., 11, 10.1038/s41467-020-17626-2 · DOI · Paper page
- Nguyen, 2020, Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency, Nat. Biotechnol., 38, 44, 10.1038/s41587-019-0325-6 · DOI · Paper page
- Chen, 2021, Enhanced prime editing systems by manipulating cellular determinants of editing outcomes, Cell, 184, 5635, 10.1016/j.cell.2021.09.018 · DOI · Paper page
- Ferreira da Silva, 2022, Prime editing efficiency and fidelity are enhanced in the absence of mismatch repair, Nat. Commun., 13, 10.1038/s41467-022-28442-1 · DOI · Paper page
- Yarnall, 2022, Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases, Nat. Biotechnol., 41, 500, 10.1038/s41587-022-01527-4 · DOI · Paper page
- Anzalone, 2022, Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing, Nat. Biotechnol., 40, 731, 10.1038/s41587-021-01133-w · DOI · Paper page
- Jiang, 2022, Deletion and replacement of long genomic sequences using prime editing, Nat. Biotechnol., 40, 227, 10.1038/s41587-021-01026-y · DOI · Paper page
- Wang, 2022, Efficient targeted insertion of large DNA fragments without DNA donors, Nat. Methods, 19, 331, 10.1038/s41592-022-01399-1 · DOI · Paper page
- Newby, 2021, Base editing of haematopoietic stem cells rescues sickle cell disease in mice, Nature, 595, 295, 10.1038/s41586-021-03609-w · DOI · Paper page
- Siegner, 2022, Adenine base editing efficiently restores the function of Fanconi anemia hematopoietic stem and progenitor cells, Nat. Commun., 13, 10.1038/s41467-022-34479-z · DOI
- Hardouin, 2022, Adenine base editor-mediated correction of the common and severe IVS1–110 (G>A) β-thalassemia mutation, Blood, 141, 1169, 10.1182/blood.2022016629 · DOI
- Antoniou, 2022, Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression, Nat. Commun., 13, 10.1038/s41467-022-34493-1 · DOI
- Zeng, 2020, Therapeutic base editing of human hematopoietic stem cells, Nat. Med., 26, 535, 10.1038/s41591-020-0790-y · DOI · Paper page
- Li, 2023, In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model, Blood
- Zetsche, 2015, Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System, Cell, 163, 759, 10.1016/j.cell.2015.09.038 · DOI · Paper page
- Strecker, 2019, RNA-guided DNA insertion with CRISPR-associated transposases, Science, 365, 48, 10.1126/science.aax9181 · DOI · Paper page
- Pallarès-Masmitjà, 2021, Find and cut-and-transfer (FiCAT) mammalian genome engineering, Nat. Commun., 12, 7071, 10.1038/s41467-021-27183-x · DOI
- Tou, 2023, Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases, Nat. Biotechnol, 10.1038/s41587-022-01574-x · DOI
- El-Kharrag, 2022, Efficient polymer nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells, Mol. Ther., 30, 2186, 10.1016/j.ymthe.2022.02.026 · DOI
- Mitchell, 2022, Clonal dynamics of haematopoiesis across the human lifespan, Nature, 606, 343, 10.1038/s41586-022-04786-y · DOI · Paper page
- Cull, 2021, Clonal Tracking By Whole Genome Sequencing Permits Comprehensive Mapping of the Genomic Landscape in Pre- and Post-Gene Therapy Sickle Cell Patients, Blood, 138, 10.1182/blood-2021-152262 · DOI
- Arumugam, 2009, Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region, Mol. Ther., 17, 1929, 10.1038/mt.2009.183 · DOI · Paper page
- Schwarzer, 2021, Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning, Mol. Ther., 29, 3383, 10.1016/j.ymthe.2021.06.017 · DOI
- Modlich, 2006, Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity, Blood, 108, 2545, 10.1182/blood-2005-08-024976 · DOI · Paper page
- Montini, 2006, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration, Nat. Biotechnol., 24, 687, 10.1038/nbt1216 · DOI · Paper page
- Cesana, 2012, Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations, J. Clin. Invest., 122, 1667, 10.1172/JCI62189 · DOI · Paper page
- Moiani, 2012, Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts, J. Clin. Invest., 122, 1653, 10.1172/JCI61852 · DOI · Paper page
- Scholz, 2017, Lentiviral Vector Promoter is Decisive for Aberrant Transcript Formation, Hum. Gene Ther., 28, 875, 10.1089/hum.2017.162 · DOI
- de Ravin, 2022, Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency, Nat. Commun., 13, 3710, 10.1038/s41467-022-31344-x · DOI · Paper page
- Servick, 2021, Gene therapy clinical trial halted as cancer risk surfaces, Science
- 2022, 2022 ASGCT Annual Meeting Abstracts, Mol. Ther., 30, 1
- Biavasco, 2021, Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis, Nat. Commun., 12, 10.1038/s41467-021-24876-1 · DOI · Paper page
- Nelson, 2019, Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy, Nat. Med., 25, 427, 10.1038/s41591-019-0344-3 · DOI · Paper page
- Tsai, 2016, Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases, Nat. Rev. Genet., 17, 300, 10.1038/nrg.2016.28 · DOI · Paper page
- Clement, 2020, Technologies and Computational Analysis Strategies for CRISPR Applications, Mol. Cell, 79, 11, 10.1016/j.molcel.2020.06.012 · DOI
- AlJanahi, 2022, Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques, Mol. Ther., 30, 209, 10.1016/j.ymthe.2021.06.016 · DOI
- Chung, 2020, Computational Analysis Concerning the Impact of DNA Accessibility on CRISPR-Cas9 Cleavage Efficiency, Mol. Ther., 28, 19, 10.1016/j.ymthe.2019.10.008 · DOI · Paper page
- Petri, 2021, Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects, bioRxiv
- Cancellieri, 2023, Human genetic diversity alters off-target outcomes of therapeutic gene editing, Nat. Genet., 55, 34, 10.1038/s41588-022-01257-y · DOI
- Weisheit, 2021, Simple and reliable detection of CRISPR-induced on-target effects by qgPCR and SNP genotyping, Nat. Protoc., 16, 1714, 10.1038/s41596-020-00481-2 · DOI
- Park, 2022, Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing, Sci Adv, 8, 10.1126/sciadv.abo7676 · DOI · Paper page
- Nahmad, 2022, Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage, Nat. Biotechnol., 40, 1807, 10.1038/s41587-022-01377-0 · DOI · Paper page
- Turchiano, 2021, Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq, Cell Stem Cell, 28, 1136, 10.1016/j.stem.2021.02.002 · DOI · Paper page
- Amendola, 2022, CRISPRthripsis: The Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy, Stem Cells Transl. Med., 11, 1003, 10.1093/stcltm/szac064 · DOI
- Colella, 2018, Emerging Issues in AAV-Mediated In Vivo Gene Therapy, Mol. Ther. Methods Clin. Dev., 8, 87, 10.1016/j.omtm.2017.11.007 · DOI · Paper page
- Dalwadi, 2021, AAV integration in human hepatocytes, Mol. Ther., 29, 2898, 10.1016/j.ymthe.2021.08.031 · DOI · Paper page
- Nguyen, 2021, A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells, Nat. Biotechnol., 39, 47, 10.1038/s41587-020-0741-7 · DOI · Paper page
- Chandler, 2017, Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models, Hum. Gene Ther., 28, 314, 10.1089/hum.2017.009 · DOI · Paper page
- Jeong, 2020, Current Status and Challenges of DNA Base Editing Tools, Mol. Ther., 28, 1938, 10.1016/j.ymthe.2020.07.021 · DOI
- Rees, 2019, Analysis and minimization of cellular RNA editing by DNA adenine base editors, Sci. Adv., 5, 10.1126/sciadv.aax5717 · DOI · Paper page
- Gaudelli, 2020, Directed evolution of adenine base editors with increased activity and therapeutic application, Nat. Biotechnol., 38, 892, 10.1038/s41587-020-0491-6 · DOI · Paper page
- Renouf, 2014, Creating cancer translocations in human cells using Cas9 DSBs and nCas9 paired nicks, Methods Enzymol., 546, 251, 10.1016/B978-0-12-801185-0.00012-X · DOI
- Bothmer, 2017, Characterization of the interplay between DNA repair and CRISPR/Cas9-induced DNA lesions at an endogenous locus, Nat. Commun., 8, 13905, 10.1038/ncomms13905 · DOI · Paper page
- Tao, 2022, Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites, Nat. Commun., 13, 10.1038/s41467-022-31322-3 · DOI
- Levesque, 2022, Marker-free co-selection for successive rounds of prime editing in human cells, Nat. Commun., 13, 10.1038/s41467-022-33669-z · DOI
- Lovell-Badge, 2021, ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update, Stem Cell Rep., 16, 1398, 10.1016/j.stemcr.2021.05.012 · DOI · Paper page
- Sharma, 2021, The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells, Nat. Commun., 12, 10.1038/s41467-020-20792-y · DOI
- Ferrari, 2021, BAR-Seq clonal tracking of gene-edited cells, Nat. Protoc., 16, 2991, 10.1038/s41596-021-00529-x · DOI
- Ludwig, 2019, Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics, Cell, 176, 1325, 10.1016/j.cell.2019.01.022 · DOI · Paper page
- Uchida, 2021, Preclinical evaluation for engraftment of CD34 + cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models Demonstrate engraftment of gene-edited CD34 + cells in xenografts and non-human primates., Cell Rep Med, 2
- Ngom, 2018, UM171 Enhances Lentiviral Gene Transfer and Recovery of Primitive Human Hematopoietic Cells, Mol. Ther. Methods Clin. Dev., 10, 156, 10.1016/j.omtm.2018.06.009 · DOI
- Zonari, 2017, Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy, Stem Cell Rep., 8, 977, 10.1016/j.stemcr.2017.02.010 · DOI · Paper page
- Naldini, 2019, Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives, EMBO Mol. Med., 11, 10.15252/emmm.201809958 · DOI · Paper page
- Boitano, 2010, Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells, Science, 329, 1345, 10.1126/science.1191536 · DOI · Paper page
- Jackson, 2017, Targeting the aryl hydrocarbon receptor nuclear translocator complex with DMOG and Stemregenin 1 improves primitive hematopoietic stem cell expansion, Stem Cell Res., 21, 124, 10.1016/j.scr.2017.04.007 · DOI
- Casado, 2016, The Aryl Hydrocarbon Receptor Relays Metabolic Signals to Promote Cellular Regeneration, Stem Cells Int., 2016, 10.1155/2016/4389802 · DOI
- Fares, 2014, Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal, Science, 345, 1509, 10.1126/science.1256337 · DOI · Paper page
- Fares, 2017, EPCR expression marks UM171-expanded CD34+ cord blood stem cells, Blood, 129, 3344, 10.1182/blood-2016-11-750729 · DOI · Paper page
- Hoggatt, 2009, Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation, Blood, 113, 5444, 10.1182/blood-2009-01-201335 · DOI · Paper page
- Watts, 2011, Hematopoietic stem cell expansion and gene therapy, Cytotherapy, 13, 1164, 10.3109/14653249.2011.620748 · DOI
- Cutler, 2013, Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation, Blood, 122, 3074, 10.1182/blood-2013-05-503177 · DOI · Paper page
- Horwitz, 2014, Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment, J. Clin. Invest., 124, 3121, 10.1172/JCI74556 · DOI · Paper page
- Piras, 2017, Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells, EMBO Mol. Med., 9, 1198, 10.15252/emmm.201707922 · DOI · Paper page
- Mazurier, 2004, Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment, Blood, 103, 545, 10.1182/blood-2003-05-1558 · DOI · Paper page
- Walter, 2015, Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells, Nature, 520, 549, 10.1038/nature14131 · DOI · Paper page
- Ahuja, 2016, A short G1 phase imposes constitutive replication stress and fork remodelling in mouse embryonic stem cells, Nat. Commun., 7, 10.1038/ncomms10660 · DOI · Paper page
- Horn, 2002, Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons, Gene Ther., 9, 1464, 10.1038/sj.gt.3301820 · DOI
- Jang, 2007, A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche, Blood, 110, 3056, 10.1182/blood-2007-05-087759 · DOI · Paper page
- Yahata, 2011, Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells, Blood, 118, 2941, 10.1182/blood-2011-01-330050 · DOI · Paper page
- Morganti, 2022, Metabolic Regulation of Hematopoietic Stem Cells, Hemasphere, 6, 10.1097/HS9.0000000000000740 · DOI
- Farlik, 2016, DNA Methylation Dynamics of Human Hematopoietic Stem Cell Differentiation, Cell Stem Cell, 19, 808, 10.1016/j.stem.2016.10.019 · DOI · Paper page
- Dircio-Maldonado, 2018, Functional Integrity and Gene Expression Profiles of Human Cord Blood-Derived Hematopoietic Stem and Progenitor Cells Generated In Vitro., Stem Cells Transl. Med., 7, 602, 10.1002/sctm.18-0013 · doi:10.1002/sctm.18-0013
- McDermott, 2015, Chromothriptic Cure of WHIM Syndrome, Cell, 160, 686, 10.1016/j.cell.2015.01.014 · DOI · Paper page
- Hou, 2021, Somatic Reversion of a Novel IL2RG Mutation Resulting in Atypical X-Linked Combined Immunodeficiency, Genes, 13, 10.3390/genes13010035 · DOI
- Waisfisz, 1999, Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism, Nat. Genet., 22, 379, 10.1038/11956 · DOI · Paper page
- Miyazawa, 2021, Reversion Mosaicism in Primary Immunodeficiency Diseases, Front. Immunol., 12, 10.3389/fimmu.2021.783022 · DOI
- Blümich, 2021, Human CD34+ Hematopoietic Stem Cell-Engrafted NSG Mice: Morphological and Immunophenotypic Features, Vet. Pathol., 58, 161, 10.1177/0300985820948822 · DOI
- Kamel-Reid, 1988, Engraftment of immune-deficient mice with human hematopoietic stem cells, Science, 242, 1706, 10.1126/science.2904703 · DOI · Paper page
- Aryee, 2014, Immunodeficient mouse model for human hematopoietic stem cell engraftment and immune system development, Methods Mol. Biol., 1185, 267, 10.1007/978-1-4939-1133-2_18 · DOI
- Walsh, 2017, Humanized Mouse Models of Clinical Disease, Annu. Rev. Pathol., 12, 187, 10.1146/annurev-pathol-052016-100332 · DOI · Paper page
- Wen, 2021, Single-cell RNA sequencing reveals the landscapes of human cord blood hematopoietic stem cell differentiation during ex vivo culture, Clin. Transl. Med., 11, 10.1002/ctm2.616 · doi:10.1002/ctm2.616
- Mende, 2022, Unique molecular and functional features of extramedullary hematopoietic stem and progenitor cell reservoirs in humans, Blood, 139, 3387, 10.1182/blood.2021013450 · DOI
- Belluschi, 2018, Myelo-lymphoid lineage restriction occurs in the human haematopoietic stem cell compartment before lymphoid-primed multipotent progenitors, Nat. Commun., 9, 10.1038/s41467-018-06442-4 · DOI · Paper page
- Calvanese, 2022, Mapping human haematopoietic stem cells from haemogenic endothelium to birth, Nature, 604, 534, 10.1038/s41586-022-04571-x · DOI · Paper page
- Calvanese, 2019, MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment, Nature, 576, 281, 10.1038/s41586-019-1790-2 · DOI · Paper page
- Luff, 2022, Identification of a retinoic acid-dependent haemogenic endothelial progenitor from human pluripotent stem cells, Nat. Cell Biol., 24, 616, 10.1038/s41556-022-00898-9 · DOI
- Ditadi, 2017, A view of human haematopoietic development from the Petri dish, Nat. Rev. Mol. Cell Biol., 18, 56, 10.1038/nrm.2016.127 · DOI · Paper page
- Ivanovs, 2017, Human haematopoietic stem cell development: from the embryo to the dish, Development, 144, 2323, 10.1242/dev.134866 · DOI · Paper page
- Capo, 2021, Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis, Haematologica, 106, 74, 10.3324/haematol.2019.238261 · DOI
- Sakurai, 2023, Chemically defined cytokine-free expansion of human haematopoietic stem cells, Nature, 615, 127, 10.1038/s41586-023-05739-9 · DOI · Paper page
- Bai, 2019, Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel, Nat. Med., 25, 1566, 10.1038/s41591-019-0601-5 · DOI · Paper page
- Piras, 2021, Antiviral immunity and nucleic acid sensing in haematopoietic stem cell gene engineering, Gene Ther., 28, 16, 10.1038/s41434-020-0175-3 · DOI
- Rehwinkel, 2020, RIG-I-like receptors: their regulation and roles in RNA sensing, Nat. Rev. Immunol., 20, 537, 10.1038/s41577-020-0288-3 · DOI · Paper page
- Decout, 2021, The cGAS-STING pathway as a therapeutic target in inflammatory diseases, Nat. Rev. Immunol., 21, 548, 10.1038/s41577-021-00524-z · DOI · Paper page
- Sumner, 2020, Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA, EMBO J., 39, 10.15252/embj.2019103958 · DOI
- Wienert, 2018, In vitro-transcribed guide RNAs trigger an innate immune response via the RIG-I pathway, PLoS Biol., 16, 10.1371/journal.pbio.2005840 · DOI · Paper page
- Wu, 2018, Intrinsic Immunity Shapes Viral Resistance of Stem Cells, Cell, 172, 423, 10.1016/j.cell.2017.11.018 · DOI · Paper page
- Petrillo, 2018, Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells, Cell Stem Cell, 23, 820, 10.1016/j.stem.2018.10.008 · DOI · Paper page
- Shi, 2018, mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3, Proc. Natl. Acad. Sci. USA, 115, E10069, 10.1073/pnas.1811892115 · DOI
- Ozog, 2019, Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes, Blood, 134, 1298, 10.1182/blood.2019000040 · DOI
- Heffner, 2018, Prostaglandin E2 Increases Lentiviral Vector Transduction Efficiency of Adult Human Hematopoietic Stem and Progenitor Cells, Mol. Ther., 26, 320, 10.1016/j.ymthe.2017.09.025 · DOI · Paper page
- Masiuk, 2019, PGE2 and Poloxamer Synperonic F108 Enhance Transduction of Human HSPCs with a β-Globin Lentiviral Vector, Mol. Ther. Methods Clin. Dev., 13, 390, 10.1016/j.omtm.2019.03.005 · DOI
- Evans, 2014, TRIM5α variations influence transduction efficiency with lentiviral vectors in both human and rhesus CD34(+) cells in vitro and in vivo, Mol. Ther., 22, 348, 10.1038/mt.2013.256 · DOI
- Cavazzana, 2017, Gene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow’s Point of View, Stem Cells Dev., 26, 71, 10.1089/scd.2016.0230 · DOI
- Canarutto, 2021, Peripheral blood stem and progenitor cell collection in pediatric candidates for ex vivo gene therapy: a 10-year series, Mol. Ther. Methods Clin. Dev., 22, 76, 10.1016/j.omtm.2021.05.013 · DOI
- Körbling, 2001, Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?, Blood, 98, 2900, 10.1182/blood.V98.10.2900 · DOI · Paper page
- Scala, 2021, Haematopoietic reconstitution dynamics of mobilized peripheral blood-and bone marrow-derived haematopoietic stem/progenitor cells after gene therapy, Hum Gene Ther, 23
- Steidl, 2002, Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells, Blood, 99, 2037, 10.1182/blood.V99.6.2037 · DOI · Paper page
- Thornley, 2001, Differences in cell cycle kinetics of candidate engrafting cells in human bone marrow and mobilized peripheral blood, Exp. Hematol., 29, 525, 10.1016/S0301-472X(00)00683-4 · doi:10.1016/s0301-472x(00)00683-4
- Donahue, 1996, Peripheral Blood CD34+ Cells Differ From Bone Marrow CD34+ Cells in Thy-1 Expression and Cell Cycle Status in Nonhuman Primates Mobilized or Not Mobilized With Granulocyte Colony-Stimulating Factor and/or Stem Cell Factor, Blood, 87, 1644, 10.1182/blood.V87.4.1644.bloodjournal8741644 · DOI
- Sereni, 2018, Autonomous role of Wiskott-Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation, J. Allergy Clin. Immunol., 142, 1272, 10.1016/j.jaci.2017.12.1000 · DOI
- Wilkinson, 2021, Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice, Nat. Commun., 12, 10.1038/s41467-021-20909-x · DOI
- Miccio, 2008, In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia, Proc. Natl. Acad. Sci. USA, 105, 10547, 10.1073/pnas.0711666105 · DOI · Paper page
- Ramírez, 2021, Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients, Am. J. Hematol., 96, 989, 10.1002/ajh.26234 · doi:10.1002/ajh.26234
- Gentner, 2019, Vivo Selection for Gene-Corrected HSPCs Advances Gene Therapy for a Rare Stem Cell Disease, Cell Stem Cell, 25, 592, 10.1016/j.stem.2019.10.004 · DOI
- Aprile, 2020, Hematopoietic stem cell function in β-thalassemia is impaired and is rescued by targeting the bone marrow niche, Blood, 136, 610, 10.1182/blood.2019002721 · DOI
- Tang, 2021, Murine bone marrow mesenchymal stromal cells have reduced hematopoietic maintenance ability in sickle cell disease, Blood, 138, 2570, 10.1182/blood.2021012663 · DOI
- Crippa, 2019, Bone marrow stromal cells from β-thalassemia patients have impaired hematopoietic supportive capacity, J. Clin. Invest., 129, 1566, 10.1172/JCI123191 · DOI
- Aprile, 2022, Targeting the Hematopoietic Stem Cell Niche in β-Thalassemia and Sickle Cell Disease, Pharmaceuticals, 15, 10.3390/ph15050592 · DOI
- Park, 2020, Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion, Blood, 135, 2071, 10.1182/blood.2019002227 · DOI
- Dalle Carbonare, 2015, Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease, Blood, 126, 2320, 10.1182/blood-2015-04-641969 · DOI
- Catucci, 2014, Wiskott–Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity, Eur. J. Immunol., 44, 1039, 10.1002/eji.201343935 · DOI
- Yuan, 2022, Wiskott-Aldrich syndrome protein forms nuclear condensates and regulates alternative splicing, Nat. Commun., 13
- Goyal, 2022, Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease, N. Engl. J. Med., 386, 138, 10.1056/NEJMoa2109167 · DOI · Paper page
- Philippidis, 2021, After Analysis, Bluebird Bio Says Vector “Very Unlikely” Cause of Acute Myeloid Leukemia, Hum. Gene Ther., 32, 332, 10.1089/hum.2021.29159.bfs · doi:10.1089/hum.2021.29159.bfs
- Kanter, 2023, Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study, Am. J. Hematol., 98, 11, 10.1002/ajh.26741 · DOI · Paper page
- Jones, 2021, Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither, Blood, 138, 942, 10.1182/blood.2021011488 · DOI · Paper page
- Seminog, 2016, Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study, J. R. Soc. Med., 109, 303, 10.1177/0141076816651037 · DOI · Paper page
- Brunson, 2017, Increased risk of leukemia among sickle cell disease patients in California, Blood, 130, 1597, 10.1182/blood-2017-05-783233 · DOI · Paper page
- Bernardo, 2016, The Role of Conditioning in Hematopoietic Stem-Cell Gene Therapy, Hum Gene Ther, 10.1089/hum.2016.103 · DOI
- Charlesworth, 2022, Immunological barriers to haematopoietic stem cell gene therapy, Nat. Rev. Immunol., 22, 719, 10.1038/s41577-022-00698-0 · DOI
- Fumagalli, 2022, Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access, Lancet, 399, 372, 10.1016/S0140-6736(21)02017-1 · DOI · Paper page
- George, 2019, Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance, Cell Stem Cell, 25, 185, 10.1016/j.stem.2019.05.018 · DOI
- Chhabra, 2016, Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy, Sci. Transl. Med., 8, 10.1126/scitranslmed.aae0501 · DOI · Paper page
- Griffin, 2022, Worked to the bone: antibody-based conditioning as the future of transplant biology, J. Hematol. Oncol., 15
- Ghannam, 2020, Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation, Blood, 135, 1185
- Agarwal, 2021, JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID), Blood, 138, 554, 10.1182/blood-2021-153074 · doi:10.1182/blood-2021-153074
- Pearse, 2019, A CD117-Amanitin Antibody Drug Conjugate (ADC) Effectively Depletes Human and Non-Human Primate Hematopoietic Stem and Progenitor Cells (HSPCs): targeted Non-Genotoxic Conditioning for Bone Marrow Transplant, Biol. Blood Marrow Transplant., 25, S29, 10.1016/j.bbmt.2018.12.101 · doi:10.1016/j.bbmt.2018.12.101
- Omer-Javed, 2022, Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells, Cell, 185, 2248, 10.1016/j.cell.2022.04.039 · DOI
- Wang, 2022, In vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4, Blood Adv., 6, 4360, 10.1182/bloodadvances.2022007975 · DOI
- Felker, 2022, Differential CXCR4 expression on hematopoietic progenitor cells versus stem cells directs homing and engraftment, JCI Insight, 7, 10.1172/jci.insight.151847 · DOI
- Bessy, 2021, Bioengineering the Bone Marrow Vascular Niche, Front. Cell Dev. Biol., 9, 10.3389/fcell.2021.645496 · DOI
- Chen, 2022, Live-seq enables temporal transcriptomic recording of single cells, Nature, 608, 733, 10.1038/s41586-022-05046-9 · DOI · Paper page
- Hoersten, 2022, Pairing of single mutations yields obligate Cre-type site-specific recombinases, Nucleic Acids Res., 50, 1174, 10.1093/nar/gkab1240 · DOI
200 of 204 shown
Cited by
Genotoxic effects of base and prime editing in human hematopoietic stem cells
Fiumara, M., Ferrari, S., Omer-Javed, A., Beretta, S., Albano, L., Canarutto, D., Varesi, A., Gaddoni, C., Brombin, C., Cugnata, F., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01915-4 · Cited by 220
“In the last decade, CRISPR–Cas-engineered nucleases coupled with a single guide RNA (gRNA) have been widely used to introduce site-specific DNA double-strand breaks (DSBs) 2,3 .”
Self-citationEngineered stem cells by emerging biomedical stratagems
Wang, J., Zhang, X., Chen, H., Ren, H., Zhou, M., & Zhao, Y. (2024) · Science Bulletin · doi:10.1016/j.scib.2023.12.006 · Cited by 37
Castiello, M. C., Brandas, C., Ferrari, S., Porcellini, S., Sacchetti, N., Canarutto, D., Draghici, E., Merelli, I., Barcella, M., Pelosi, G., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh8162 · Cited by 25
Self-citationBalancing efficacy and safety in lentiviral vector-mediated hematopoietic stem cell gene therapy
Montini, E., Naldini, L., Booth, C., Kohn, D. B., & Aiuti, A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.028 · Cited by 18
Self-citation
Metadata
- Authors
- Ferrari, S., Valeri, E., Conti, A., Scala, S., Aprile, A., Di Micco, R., Kajaste-Rudnitski, A., Montini, E., Ferrari, G., Aiuti, A., & Naldini, L.
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 30
- Issue
- 5
- Pages
- 549-570
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- OpenAlex
- W4368363424
- Cited by
- 70
- References
- 73
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 369 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Lady Tata Memorial Trust
- Louis-Jeantet Foundation
- Fondazione Telethon
- American Society of Hematology
- Else Kröner-Fresenius-Stiftung
- New York Stem Cell Foundation
- Ministero della Salute (E-Rare-3, GR-2018-12366006, GR-2019-12369499)
- Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN2017)
- European Research Council
- European Hematology Association
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.